StockData
Chemomab Therapeutics Ltd. logo

Chemomab Therapeutics Ltd. (CMMB) stock

CMMBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026Score 5/30
$1.62+0.09 (+5.88%)

Close on Nov 16, 2026Market cap $11.65MP/E 1.1Yield –

Earnings

Chemomab Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q2 FY2026
–
EPS, Q2 FY2026
$0.00
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Chemomab Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q2 FY2026ended Jun 30, 2026Aug 19, 2026before the open––$0.00Release
Q1 FY2026ended Mar 31, 2026May 14, 2026before the open––$0.00Release
Q2 FY2025ended Jun 30, 2025Aug 14, 2025before the open–––Release
Q1 FY2025ended Mar 31, 2025May 15, 2025before the open––$0.01Release
Q4 FY2024ended Dec 31, 2024Mar 3, 2025before the open––$0.01Release
Q2 FY2024ended Jun 30, 2024Aug 21, 2024before the open––$0.01Release
Q1 FY2024ended Mar 31, 2024May 9, 2024before the open––$0.01Release
Q4 FY2023ended Dec 31, 2023Mar 7, 2024before the open––$0.01Release
Q2 FY2023ended Jun 30, 2023Aug 14, 2023before the open––$0.04Release
Q1 FY2023ended Mar 31, 2023May 11, 2023before the open––-$0.04Release
Q4 FY2022ended Dec 31, 2022Feb 21, 2023before the open–––Release
Q2 FY2022ended Jun 30, 2022Aug 12, 2022before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Chemomab Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Chemomab Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Chemomab Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. 6-K
  2. 6-K
  3. 6-K
  4. 6-K
  5. 6-K
  6. 6-K
  7. 6-K
  8. 6-K
  9. 6-K
  10. 6-K
  11. 6-K
  12. 6-K
  13. 6-K
  14. 6-K
  15. 6-K

See a number that looks wrong?